Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: Insulin degludec (Des(B30)LysB29(γ-Glu Nε-hexadecandioyl) human insulin; IDeg) is a new basal insulin with an ultra-long flat action profile. The acute physiological responses to hypoglycaemia with IDeg and insulin glargine (A21Gly,B31Arg,B32Arg human insulin; IGlar) were compared. METHODS: Twenty-eight adult type 1 diabetic patients with normal hypoglycaemia awareness (age = 41 ± 12 years, HbA1c = 7.8 ± 0.6% [62.8 ± 7 mmol/mol]) were randomised to once-daily IDeg or IGlar for 5 days in a two-period crossover design. Participants and research staff were blinded to group assignment. Patients were assigned the lowest available randomisation number from a set of blinded randomisation codes provided by the trial sponsor. Hypoglycaemia was induced by administering three times the usual daily insulin dose at midnight on day 5. Plasma glucose (PG) was stabilised by glucose clamp (5.5 mmol/l) for 7-9 h post dosing. Next morning, PG was allowed to decrease stepwise from 5.5 to 3.5 mmol/l (maintained for 30 min) to 2.5 mmol/l (for 15 min). PG was then increased to 3.9 mmol/l (for 120 min), before being returned to baseline. Hypoglycaemic symptom score (HSS), hypoglycaemic awareness, cognitive function, counter-regulatory hormones and vital signs were assessed during each glucose plateau. The primary analysis was to compare IDeg vs IGlar with respect to HSS at nadir PG concentration (2.5 mmol/l). RESULTS: The full analysis set for treatment comparisons comprised data from all 28 exposed patients. Rates of PG decline and PG at nadir were similar for IDeg and IGlar. No treatment differences in HSS (estimated difference: 0.17 [95% CI -1.71, 2.05]; p > 0.05), cognitive function or awareness were observed at any time. Growth hormone and cortisol responses during hypoglycaemia were greater with IDeg than IGlar (AUC treatment ratio [IDeg/IGlar]: 2.44 [1.30, 4.60], p < 0.01; and 1.23 [1.01, 1.50]; p < 0.05), and adrenaline (epinephrine) responses trended higher (1.40 [0.96, 2.04], p = 0.07). The rates of recovery from hypoglycaemia were similar. CONCLUSIONS/INTERPRETATION: IDeg and IGlar elicit comparable symptomatic and cognitive responses to induced hypoglycaemia. IDeg may elicit a moderately greater endocrine response, but times to PG recovery were similar for the two insulins. TRIAL REGISTRATION: ClinicalTrials.gov NCT01002768. FUNDING: Novo Nordisk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The study therefore showed that the longer duration of action of IDeg than of IGlar does not affect the nature of, or time to recovery from, a hypoglycaemic episode [58].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [58]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a double-blind, randomised, crossover trial was conducted in subjects with T1DM to investigate the impact of IDeg on the counter-regulatory hormone response to hypoglycaemia during the development of and recovery from hypoglycaemia, compared with subjects receiving IGlar [58].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“During recovery from hypoglycaemia, mean HSS returned to baseline at a similar rate for IDeg and IGlar.”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2001) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/j.1447-0756.2001.tb01222.x · Cited by 3,461
Ethical principles for medical research involving human subjects
(2003) · Manual for Research Ethics Committees · doi:10.1017/cbo9780511550089.027 · Cited by 2,585
Abraham, J. (2010) · Handbook of Transnational Economic Governance Regimes · doi:10.1163/ej.9789004163300.i-1081.897 · Cited by 2,582
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
(2014) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/jwiet-2014-0117 · Cited by 2,473
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069
WAIS-R manual : Wechsler adult intelligence scale-revised
Wechsler, D. (1981) · Medical Entomology and Zoology · Cited by 1,559
Clinical neuropsychology: Current status and applications
(1975) · Behavior Therapy · doi:10.1016/s0005-7894(75)80088-8 · Cited by 1,552
Administration and interpretation of the Trail Making Test
Bowie, C. R., & Harvey, P. D. (2006) · Nature Protocols · doi:10.1038/nprot.2006.390 · Cited by 1,418 · cited 1×
“1) was evaluated by using three cognitive function tests recognised as being sensitive to hypoglycaemia [14]: trail making B [15, 16]; digit symbol substitution test [17]; and the four-choice reaction time [18].”
MethodRisk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
Gold, A. E., Macleod, K. M., & Frier, B. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.697 · Cited by 810 · cited 1×
“Severe episodes of hypoglycaemia are less frequent in patients with diabetes who still have hypoglycaemia awareness [2], but these patients are still at significant risk of hypoglycaemia due to lack of adequate glucagon secretion and a reduced response of other counter-regulatory hormones [1].”
BackgroundICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice.
Bhuiyan, P. S., & Rege, N. N. (2001) · PubMed · Cited by 527
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448
Heller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A. M. O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60204-9 · Cited by 402
Self-citationHeise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397 · cited 1×
“Insulin degludec (Des(B30)LysB29(γ-Glu Nε-hexadecandioyl) human insulin; IDeg) is a new ultralong-acting basal insulin analogue with an extended duration of action beyond 42 h [4], a flat insulin profile with once-daily dosing [5] and lower intrapatient variability [6].”
BackgroundSelf-citationRatner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12032 · Cited by 346 · cited 1×
“Using IDeg, insulin-naive and insulin-treated patients with type 2 diabetes showed a significantly reduced risk of overall and nocturnal hypoglycaemia events [7]; in patients with type 1 diabetes, a similar result regarding nocturnal hypoglycaemia was found [8, 9].”
ResultGarber, A. J., King, A. B., Prato, S. D., Sreenan, S., Balci, M. K., Muñoz-Torres, M., Rosenstock, J., Endahl, L. A., Francisco, A. M. O., & Hollander, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60205-0 · Cited by 325
Symptoms of hypoglycaemia in people with diabetes
McAulay, V., Deary, I. J., & Frier, B. M. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00620.x · Cited by 264 · cited 2×
“This scale classifies hypoglycaemic symptoms into autonomic symptoms (sweating, palpitations, shaking and hunger), neuroglycopenic symptoms (confusion, drowsiness, odd behaviour, speech difficulty and incoordination) and non-specific symptoms (headache and nausea) [12, 13].”
BackgroundMethodHypoglycemia in Type 1 Diabetes
McCrimmon, R. J., & Sherwin, R. S. (2010) · Diabetes · doi:10.2337/db10-0103 · Cited by 217 · cited 1×
“Furthermore, with a longer duration of type 1 diabetes the risk for hypoglycaemia increases and hypoglycaemia awareness becomes reduced [3].”
BackgroundFanelli, C., Pampanelli, S., Epifano, L., Rambotti, A. M., Di Vincenzo, A., Modarelli, F., Ciofetta, M., Lepore, M., Annibale, B., Torlone, E., et al. (1994) · Diabetologia · doi:10.1007/bf00399801 · Cited by 212
Davis, S. N., Shavers, C., Costa, F., & Mosqueda-Garcia, R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118839 · Cited by 173 · cited 1×
“Elevated cortisol levels have been associated with autonomic failure [26] but more recent studies could not confirm this finding [27, 28].”
ResultInsulin Degludec in Type 1 Diabetes
Birkeland, K. I., Home, P. D., Wendisch, U., Ratner, R. E., Johansen, T., Endahl, L. A., Lyby, K., Jendle, J. H., Roberts, A. P., DeVries, J. H., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1925 · Cited by 160
Portable four-choice reaction time test with magnetic tape memory
Wilkinson, R. T., & Houghton, D. (1975) · Behavior Research Methods · doi:10.3758/bf03201557 · Cited by 155 · cited 1×
“1) was evaluated by using three cognitive function tests recognised as being sensitive to hypoglycaemia [14]: trail making B [15, 16]; digit symbol substitution test [17]; and the four-choice reaction time [18].”
MethodZinman, B., Fulcher, G., Rao, P. V., Thomas, N., Endahl, L. A., Johansen, T., Lindh, R., Lewin, A. J., Rosenstock, J., Pinget, M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62305-7 · Cited by 138
Hypoglycaemia in Clinical Diabetes
(2007) · Wiley eBooks · doi:10.1002/9780470516270 · Cited by 120
Insulin degludec: overview of a novel ultra long‐acting basal insulin
Gough, S. C. L., Harris, S., Woo, V., & Davies, M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12052 · Cited by 74 · cited 1×
“Insulin degludec (Des(B30)LysB29(γ-Glu Nε-hexadecandioyl) human insulin; IDeg) is a new ultralong-acting basal insulin analogue with an extended duration of action beyond 42 h [4], a flat insulin profile with once-daily dosing [5] and lower intrapatient variability [6].”
BackgroundGALASSETTI, P., & DAVIS, S. N. (2000) · Clinical Science · doi:10.1042/cs0990351 · Cited by 72 · cited 1×
“As glucagon responses to hypoglycaemia are attenuated by both type 1 diabetes and hyperinsulinaemia [21], it is not surprising that no differences in glucagon response were observed.”
BackgroundSymptoms of Hypoglycaemia and Effects on Mental Performance and Emotions
Deary, I. J., & Zammitt, N. N. (2014) · Hypoglycaemia in Clinical Diabetes · doi:10.1002/9781118695432.ch2 · Cited by 56 · cited 1×
“1) was evaluated by using three cognitive function tests recognised as being sensitive to hypoglycaemia [14]: trail making B [15, 16]; digit symbol substitution test [17]; and the four-choice reaction time [18].”
MethodRaju, B., McGregor, V. P., & Cryer, P. E. (2003) · Diabetes · doi:10.2337/diabetes.52.8.2083 · Cited by 46 · cited 1×
“Elevated cortisol levels have been associated with autonomic failure [26] but more recent studies could not confirm this finding [27, 28].”
ResultHypoglycaemia and cognitive function in diabetes.
Frier, B. M. (2001) · PubMed · Cited by 39
Smeeton, F., Shojaee‐Moradie, F., Jones, R. H., Westergaard, L., Haahr, H. L., Umpleby, A. M., & Russell-Jones, D. L. (2009) · Diabetologia · doi:10.1007/s00125-009-1487-4 · Cited by 34 · cited 1×
“5 [19] and a significance level of 5%, it was calculated that 26 completers were required to yield sufficient power (83%) to detect an eight point difference between IDeg and IGlar.”
BackgroundSelf-citationGoldberg, P. A., Weiss, R., McCrimmon, R. J., Hintz, E. V., Dziura, J. D., & Sherwin, R. S. (2006) · Diabetes · doi:10.2337/diabetes.55.04.06.db05-1169 · Cited by 34
Rossetti, P., Porcellati, F., Ricci, N. B., Candeloro, P., Cioli, P., Bolli, G. B., & Fanelli, C. G. (2007) · Diabetes · doi:10.2337/db07-1433 · Cited by 33 · cited 1×
“Finally, we included people with type 1 diabetes, rather than healthy patients, to ensure the pharmacodynamic response was not confounded by endogenous insulin production [20–22].”
Frier, B. M., Ewing, F. M. E., Lindholm, A., Hylleberg, B., & Kanc, K. (2000) · Diabetes/Metabolism Research and Reviews · doi:10.1002/1520-7560(2000)9999:9999<::aid-dmrr120>3.0.co;2-1 · Cited by 26 · cited 1×
“delivery [23–25], we considered s.”
Heller, S. R. (1999) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1053/beem.1999.0020 · Cited by 24
Self-citationDagogo‐Jack, S., Askari, H., Morrill, B., Lehner, L. L., Kim, B., & Sha, X. (2000) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00109.x · Cited by 23 · cited 1×
“Comparable physiological responses to induced hypoglycaemia have been shown for IGlar and human insulin in a stepped hypoglycaemic clamp [24] and clinical trials have shown comparable glycaemic control with IDeg and IGlar when treated to target [31, 32].”
BackgroundSymptoms of Hypoglycaemia and Effects on Mental Performance and Emotions
Deary, I. J. (2007) · Hypoglycaemia in Clinical Diabetes · doi:10.1002/9780470516270.ch2 · Cited by 23
Insulin detemir causes increased symptom awareness during hypoglycaemia compared to human insulin
Tschritter, O., Schäfer, S., Klett, J., Pfäfflin, A., Häring, H., Hennige, A. M., & Fritsche, A. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01085.x · Cited by 20 · cited 1×
“Finally, we included people with type 1 diabetes, rather than healthy patients, to ensure the pharmacodynamic response was not confounded by endogenous insulin production [20–22].”
Galassetti, P. R., & Davis, S. N. (2000) · Clinical Science · doi:10.1042/cs20000022 · Cited by 15
Insulin glargine versus NPH insulin in patients with type 1 diabetes
Ratner, R. E. (2003) · Drugs of today · doi:10.1358/dot.2003.39.11.799464 · Cited by 9 · cited 1×
“Although basal insulins such as IGlar are associated with a reduction in severe and nocturnal hypoglycaemia compared with neutral protamine Hagedorn insulin [29, 30], this appears to be due to improvements in insulin kinetics rather than to differences in glucose counter-regulation.”
Background
Cited by
A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
Haahr, H., & Heise, T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0165-y · Cited by 226
“The study therefore showed that the longer duration of action of IDeg than of IGlar does not affect the nature of, or time to recovery from, a hypoglycaemic episode [58].”
BackgroundResultSelf-citationClinical use of insulin degludec
Vora, J., Cariou, B., Evans, M., Gross, J. L., Harris, S., Landstedt-Hallin, L., Mithal, A., Rodriguez, M. R., & Meneghini, L. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.002 · Cited by 73
“[54] Koehler G, Heller S, Korsatko S, Roepstorff C, Rasmussen S, Haahr H, et al.”
BackgroundResultMoser, O., Mader, J., Tschakert, G., Mueller, A., Groeschl, W., Pieber, T., Koehler, G., Messerschmidt, J., & Hofmann, P. (2016) · Nutrients · doi:10.3390/nu8080489 · Cited by 60
Self-citationPieber, T. R., Deller, S., Korsatko, S., Jensen, L., Christiansen, E., Madsen, J., & Heller, S. R. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12473 · Cited by 43
“At the end of each 4-week treatment period, a stepwise hypoglycaemic clamp was performed (Figure 1B) [25].”
MethodSelf-citationDegludec: the new ultra-long insulin analogue
Tambascia, M. A., & Eliaschewitz, F. G. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0037-0 · Cited by 41
“Still regarding IDeg and hypoglycemia, a double-blind randomized crossover study using stepwise hypoglycemic clamp has demonstrated that symptomatic and cognitive responses to induced hypoglycemia, as well as the time required for glycemia recovery are similar between IDeg and IGlar, reassuring the safety profile of I…”
Background
Metadata
- Authors
- Koehler, G., Heller, S., Korsatko, S., Roepstorff, C., Rasmussen, S., Haahr, H., & Pieber, T. R.
- Affiliations
- University of Graz (AT)
- University of Sheffield (GB)
- Novo Nordisk (Denmark) (DK)
- Corresponding author
- Pieber, Thomas R.
- Venue
- Diabetologia
- Published
- 2013-09-22
- Volume
- 57
- Issue
- 1
- Pages
- 40-49
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC3855490
- OpenAlex
- W2097913137
- Semantic Scholar
- 9e7cd98f4d2b2fa54fb3538e2659baee80234184
- Cited by
- 29
- References
- 38
- Citations by year
- 2026: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 4 · 2016: 6 · 2015: 7 · 2014: 5
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetologia (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- MannKind Corporation
- National Institute for Health and Care Research (NF-SI-0611-10248)
- Novo Nordisk
- Karl-Franzens-Universität Graz
- Medizinische Universität Graz
- Servier
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- insulin degludec, insulin glargine, type 1 diabetes, hypoglycemia, growth hormone, cortisol, cognitive function, basal insulin, glucose clamp, insulin pharmacokinetics, insulin pharmacodynamics
- MeSH terms
- Insulin Glargine, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Double-Blind Method, Female, Humans, Hypoglycemia, Male, Middle Aged, Cross-Over Studies, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.